2025-06-13
Recently, Yin Ye, the CEO of BGI Group, shared some exciting anticancer news on video channels such as "Liao Yibo Caijing", which sparked heated discussions on WeChat Moments. He mentioned that Japan has recently launched a cutting - edge cancer treatment technology known as the "seventh chariot", called BNCT, which is translated into Chinese as Boron Neutron Capture Therapy.
2025-06-12
A policy adjustment by the US FDA has stirred up quite a storm in the pharmaceutical R & D industry. Recently, the FDA announced that in the development of drugs such as monoclonal antibodies, it will gradually reduce, optimize, or replace animal testing, and instead rely on AI - based toxicity models, cell lines, and organoid tests. The simultaneously released "Roadmap for Reducing Animal Testing in Pre - clinical Safety Studies" further outlines a strategic vision for gradually moving away from dependence on animals.
2025-06-05
Recently, a research team from Tianjin University published a study in Engineering, designing a novel antifreeze peptide, AVD, by mimicking the "molecular Lego" of Antarctic bacterial antifreeze proteins. Experiments show that frozen cells supplemented with AVD achieved a recovery rate of up to 95.7%, tripling the efficiency of conventional methods.
2025-04-25
New Flexible Auditory Brainstem Implant Offers Hope for Patients with Severe Hearing Loss
A research team from the Swiss Federal Institute of Technology Lausanne (EPFL) recently published a groundbreaking achievement in Nature Biomedical Engineering: the world’s first flexible auditory brainstem implant (ABI). This innovative technology aims to address the side effects caused by the rigid structure of traditional ABIs, offering a more precise and safe hearing restoration solution for patients with severe cochlear nerve damage who cannot benefit from cochlear implants.
2025-04-25
Nature Medicine Review: AI Reconstructs the Paradigm of Drug Development
In the prolonged battle between humanity and disease, drug development remains the decisive battleground. Faced with the harsh reality of an average investment of $2.6 billion, a 15-year timeline, and a success rate below 10%, global scientists are turning to artificial intelligence (AI). This disruptive technology is quietly ushering drug development into a new era of "algorithm-driven" innovation. By 2025, the latest research in Nature journals reveals that generative AI models, exemplified by ChatGPT and Sora, are reshaping the entire drug development pipeline—from target discovery to clinical trials—accelerating "AI-driven drug discovery" from concept to clinical practice.
2025-04-18
Imagine if immune cells in the human body could transform into "smart missiles," relentlessly tracking and destroying cancer cells without harming healthy tissue—this would revolutionize cancer treatment. A groundbreaking announcement from the USC Viterbi School of Engineering reveals the arrival of "EchoBack CAR T cells", a new breed of "thinking" immune warriors propelling targeted cancer therapy into a 2.0 era!
2025-04-17
Gene Scissors 2.0 Unveiled! New Tech Enables "Precision Gene Transplantation"
Nature hailed the breakthrough: "STITCHR fills critical technological gaps and heralds a new era of precision medicine." As clinical trials advance, this molecular revolution—orchestrated by RNA and jumping genes—is set to redefine humanity’s foundational approach to combating disease.
2025-04-11
These advancements demonstrate the feasibility of gene-editing and cloning in resurrecting extinct species, attracting increased funding and scientific collaboration. This progress elevates genetic technology’s potential in biodiversity conservation, biopharmaceuticals, and beyond, heralding a new era of ecological restoration and innovation.
2025-04-11
On April 8 (Tuesday), Xijing Hospital of Air Force Medical University announced a major breakthrough in Asia’s first gene-edited pig kidney transplant for a patient with end-stage renal disease. The patient has maintained stable kidney function for 32 days post-surgery and met discharge standards. This achievement marks a milestone in China’s clinical research on xenotransplantation, offering new hope for patients with terminal kidney disease.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
